Cellular and T cell engager Immunotherapy
QUINTESSENTIAL: a multicenter phase 2 study evaluating the efficacy and safety of BMS-986393 in patients with quadruple-class exposed relapsed or refractory multiple myeloma
Krina K. Patel, MD (she/her/hers)
Associate Professor
MD Anderson Cancer Center, University of Texas, Houston, TX, USA
Houston, Texas, United States